Therapeutic Gold Compounds

Ligand Design in Medicinal Inorganic Chemistry

Volumn 9781118488522, Issue , 2014, Pages 227-256

  Berners Price, Susan J ^a   Barnard, Peter J ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Antiarthritic agents; Antiparasitic agents; Antitumour agents; Au(I) compounds; Au(III) compounds; Auranofin; Cancer; Gold; Ligand design; Malaria; N Heterocyclic carbene; Phosphine; Rheumatoid arthritis; Thiosemicarbazone

Indexed keywords

AMINO ACIDS; BIOACTIVITY; CONTROLLED DRUG DELIVERY; DISEASES; ENZYME INHIBITION; LIGANDS; PHOSPHORUS COMPOUNDS; TARGETED DRUG DELIVERY;

ANTIARTHRITIC AGENT; ANTIPARASITIC AGENTS; ANTITUMOUR AGENTS; AU(I) COMPOUND; AU(III) COMPOUND; AURANOFIN; CANCER; GOLD; LIGAND DESIGN; MALARIA; N-HETEROCYCLIC CARBENES; PHOSPHINE; RHEUMATOID ARTHRITIS; THIOSEMICARBAZONES;

GOLD COMPOUNDS;

EID: 84927124827     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118697191.ch9     Document Type: Chapter

References (209)

1. Higby, G.J. (1982) Gold in medicine. Gold Bull., 15, 130-140.
2. Zhao, H. and Ning, Y. (2001) China's ancient gold drugs. Gold Bull., 34, 24-29.
3. Berners-Price, S.J. (2011) Gold-based therapeutic agents: a new perspective, in Bioinorganic Medicinal Chemistry (ed E. Alessio), Wiley-VCH Verlag GmbH, Weinheim, pp. 197-221.
4. Kean,W.F., Forestier, F., Kassam, Y. et al. (1985) The history of gold therapy in rheumatoid disease. Semin. Arthritis Rheu., 14, 180-186.
5. Eisler, R. (2003) Chrysotherapy: a synoptic review. Inflamm. Res., 52, 487-501.
6. Sutton, B.M.,McGusty, E.,Walz, D.T. and DiMartino, M.J. (1972) Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. J. Med. Chem., 15, 1095-1098.
7. Sutton, B.M. (1986) Gold compounds for rheumatoid arthritis. Gold Bull., 19, 15-16.
8. Mirabelli, C.K., Johnson, R.K., Sung, C.M. et al. (1985) Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res., 45, 32-39.
9. Berners-Price, S.J., Mirabelli, C.K., Johnson, R.K. et al. (1986) In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res., 46, 5486-5493.
10. Messori, L. and Marcon, G. (2004) Gold complexes as antitumor agents. Met. Ions Biol. Syst., 42, 385-424.
11. Barnard, P.J. and Berners-Price, S.J. (2007) Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev., 251, 1889-1902.
12. Gabbiani, C., Casini, A. and Messori, L. (2007) Gold(III) compounds as anticancer drugs. Gold Bull., 40, 73-81.
13. Casini, A., Hartinger, C., Gabbiani, C. et al. (2008) Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. J. Inorg. Biochem., 102, 564-575.
14. Tiekink, E.R.T. (2008) Anti-cancer potential of gold complexes. Inflammopharmacology, 16, 138-142.
15. Ott, I. (2009) On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev., 253, 1670-1681.
16. Nobili, S., Mini, E., Landini, I. et al. (2010) Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev., 30, 550-580.
17. Berners-Price, S.J. and Filipovska, A. (2011) Gold compounds as therapeutic agents for human diseases. Metallomics, 3, 863-873.
18. Gromer, S., Urig, S. and Becker, K. (2004) The thioredoxin system - from science to clinic. Med. Res. Rev., 24, 40-89.
19. Fricker, S.P. (2010) Cysteine proteases as targets for metal-based drugs. Metallomics, 2, 366-377.
20. Fricker, S.P. (2007) Metal based drugs: from serendipity to design. Dalton Trans., 4903-4917.
21. Gunatilleke, S.S. and Barrios,A.M. (2006) Inhibition of lysosomal cysteine proteases by a series ofAu(I) complexes: a detailed mechanistic investigation. J. Med. Chem., 49, 3933-3937.
22. Gunatilleke, S.S., de Oliveira, C.A.F., McCammon, J.A. and Barrios, A.M. (2008) Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study. J. Biol. Inorg. Chem., 13, 555-561.
23. Gunatilleke, S.S. and Barrios, A.M. (2008) Tuning the Au(I)-mediated inhibition of cathepsin B through ligand substitutions. J. Inorg. Biochem., 102, 555-563.
24. Weidauer, E., Yasuda, Y., Biswal, B.K. et al. (2007) Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biol. Chem., 388, 331-336.
25. Zhu, Y., Cameron, B.R., Mosi, R. et al. (2011) Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity. J. Inorg. Biochem., 105, 754-762.
26. Krishnamurthy, D., Karver, M.R., Fiorillo, E. et al. (2008) Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study. J. Med. Chem., 51, 4790-4795.
27. Zhang, Z.-Y. (2002) Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol., 42, 209-234.
28. Navarro, M. (2009) Gold complexes as potential anti-parasitic agents. Coord. Chem. Rev., 253, 1619-1626.
29. Ilari, A., Baiocco, P., Messori, L. et al. (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids, 42, 803-811.
30. Krauth-Siegel, R.L., Bauer, H. and Schirmer, H. (2005) Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew. Chem. Int. Ed., 44, 690-715.
31. Fillat, M.F., Gimeno, M.C., Laguna, A. et al. (2011) Synthesis, structure and bactericide activity of (aminophosphane) gold(I) thiolate complexes. Eur. J. Inorg. Chem., 2011, 1487-1495.
32. Jackson-Rosario, S. and Self, W.T. (2009) Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J. Bacteriol., 191, 4035-4040.
33. Jackson-Rosario, S., Cowart, D., Myers, A. et al. (2009) Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J. Biol. Inorg. Chem., 14, 507-519.
34. Blodgett, R.C.J., Heuer, M.A. and Pietrusko, R.G. (1984) Auranofin: a unique oral chrysotherapeutic agent Semin. Arthritis Rheu., 13, 255-273.
35. Shapiro, D.L. and Masci, J.R. (1996) Treatment of HIV associated psoriatic arthritis with oral gold. J. Rheumatol., 23, 1818-1820.
36. Fonteh, P.N., Keter, F.K. and Meyer, D. (2010) HIV therapeutic possibilities of gold compounds. Biometals, 23, 185-196.
37. Lewis, M.G., Dafonseca, S., Chomont, N. et al. (2011) Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS, 25, 1347-1356.
38. Sannella, A.R., Casini, A., Gabbiani, C. et al. (2008) New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett., 582, 844-847.
39. Kuntz, A.N., Davioud-Charvet, E., Sayed, A.A. et al. (2007) Thioredoxin glutathione reductase from schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med., 4, 1071-1086.
40. Debnath, A., Parsonage, D., Andrade, R.M. et al. (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med., 18, 956-960.
41. Chong, C.R. and Sullivan, D.J. (2007) New uses for old drugs. Nature, 448, 645-646.
42. Shaw, C.F. III, (1999) Gold complexes with anti-arthritic, anti-tumour and anti-HIV activity, in Uses of Inorganic Chemistry in Medicine (ed N.P. Farrell), Royal Society of Chemistry, Cambridge, pp. 26-57.
43. Bhabak, K.P., Bhuyan, B.J. andMugesh, G. (2011) Bioinorganic and medicinal chemistry: aspects of gold(I)-protein complexes. Dalton Trans., 40, 2099-2111.
44. Bau, R. (1998) Crystal structure of the antiarthritic drug gold thiomalate (myochrysine): a double-helical geometry in the solid state. J. Am. Chem. Soc., 120, 9380-9381.
45. Mazid, M.A., Razi, M.T., Sadler, P.J. et al. (1980) An EXAFS study of gold coordination in the anti-arthritic drugs myocrisin and solganol. J. Chem. Soc., Chem. Commun., 1261-1263.
46. Elder, R.C., Ludwig, K., Cooper, J.N. and Eidsness, M.K. (1985) EXAFS ANDWAXS structure determination for an antiarthritic drug, sodium gold(I) thiomalate. J. Am. Chem. Soc., 107, 5024-5025.
47. Shaw, C.F. III, (1999) Gold-based therapeutic agents. Chem. Rev., 99, 2589-2600.
48. Shaw, C.F. III, Schaeffer, N.A., Elder, R.C. et al. (1984) Bovine serum albumin-gold thiomalate complex: 197Au Mossbauer, EXAFS and XANES, electrophoresis, 35S-radiotracer, and fluorescent probe competition studies. J. Am. Chem. Soc., 106, 3511-3521.
49. Chaffman, M., Brogden, R.N., Heel, R.C. et al. (1984) Auranofin - A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs, 27, 378-424.
50. Felson, D.T., Anderson, J.J. and Meenan, R.F. (1990) The comparative efficacy and toxicity of 2nd-line drugs in rheumatoid arthritis - results of 2 metaanalyses. Arthritis Rheum., 33, 1449-1461.
51. Pope, J.E., Hong, P. and Koehler, B.E. (2002) Prescribing trends in disease modifying, antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J. Rheumatol., 29, 255-260.
52. Whitehouse, M.W., Cookson, P.D., Siasios, G. and Tiekink, E.R.T. (1998) Anti-arthritic activity in rats of some phosphinegold(I) thionucleobases and related thiolates. Metal-Based Drugs, 5, 245-249.
53. Intoccia, A.P., Flanagan, T.L., Walz, D.T. et al. (1982) Pharmacokinetics of auranofin in animals. J. Rheumatol., 9 (Suppl. 8), 90-98.
54. Coffer, M.T., Shaw, C.F.I., Hormann, A.L. et al. (1987) Thiol competition for Et3PAuS-albumin. A non enzymatic mechanism for Et3PO formation. J. Inorg. Biochem., 30, 177-187.
55. Hill, D.T., Isab, A.A., Griswold, D.E. et al. (2010) Seleno-auranofin (Et3PAuSe-tagl): synthesis, spectroscopic (EXAFS, 197Au Mössbauer, 31P, 1H, 13C, and 77Se NMR, ESI-MS) characterization, biological activity, and rapid serum albumin-induced triethylphosphine oxide generation. Inorg. Chem., 49, 7663-7675.
56. Berners Price, S.J., Dimartino, M.J., Hill, D.T. et al. (1985) Tertiary phosphine complexes of gold(I) and gold(III) with imido ligands - H-1, P-31 and N-15 NMR-spectroscopy, antiinflammatory activity, and X-ray crystal-structure of (phthalimido)(triethylphosphine)gold(I). Inorg. Chem., 24, 3425-3434.
57. Trávníček, Z., Starha, P., Vančo, J. et al. (2012) Anti-inflammatory active gold(I) complexes involving 6-substituted-purine derivatives. J. Med. Chem., 55 (10), 4568-4579.
58. Karver, M.R., Krishnamurthy, D., Bottini, N. and Barrios, A.M. (2010) Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase. J. Inorg. Biochem., 104, 268-273.
59. Karver, M.R., Krishnamurthy, D., Kulkarni, R.A. et al. (2009) Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes. J. Med. Chem., 52, 6912-6918.
60. Berners-Price, S.J. and Filipovska, A. (2008) The design of gold-based, mitochondria-targeted chemotherapeutics. Aust. J. Chem., 61, 661-668.
61. Bindoli, A., Rigobello, M.P., Scutari, G. et al. (2009) Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 253, 1692-1707.
62. Gandin, V., Fernandes, A.P., Rigobello, M.P. et al. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol., 79, 90-101.
63. Pratesi, A., Gabbiani, C.,Ginanneschi,M. and Messori, L. (2010) Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. Chem. Commun., 46, 7001-7003.
64. Tian, S., Siu, F.-M., Kui, S.C.F. et al. (2011) Anticancer gold(I)-phosphine complexes as potent autophagy-inducing agents. Chem. Commun., 47, 9318-9320.
65. Simon, T.M., Kunishima, D.H., Vibert, G.J. et al. (1979) Inhibitory effects of a new oral gold compound on HeLa cells. Cancer, 44, 1965-1975.
66. Simon, T.M., Kunishima, D.H., Vibert, G.J. and Lorber, A. (1981) Screening trial with the coordinated gold compound auranofin using mouse lymphocytic leukemia P388. Cancer Res., 41, 94-97.
67. Pearson, S., Scarano, W. and Stenzel, M.H. (2012) Micelles based on gold-glycopolymer complexes as new chemotherapy drug delivery agents. Chem. Commun., 48, 4695-4697.
68. Robilotto, T.J., Alt, D.S.,Von Recum, H.A. andGray, T.G. (2011) Cytotoxic gold(I)-bearing dendrimers from alkyne precursors. Dalton Trans., 40, 8083-8085.
69. Meyer, A., Bagowski, C.P., Kokoschka, M. et al. (2012) On the biological properties of alkynyl phosphine gold(I) complexes. Angew. Chem. Int. Ed., 51, 8895-8899.
70. Chui, C.-H.,Wong, R.S.-M., Gambari, R. et al. (2009) Antitumor activity of diethynylfluorene derivatives of gold(I). Bioorg. Med. Chem., 17, 7872-7877.
71. Balasingham, R.G., Williams, C.F., Mottram, H.J. et al. (2012) Gold(I) complexes derived from alkynyloxysubstituted anthraquinones: syntheses, luminescence, preliminary cytotoxicity, and cell imaging studies. Organometallics, 31, 5835-5843.
72. Vergara, E., Cerrada, E., Casini, A. et al. (2010) Antiproliferative activity of gold(I) alkyne complexes containing water-soluble phosphane ligands. Organometallics, 29, 2596-2603.
73. Mirabelli, C.K., Johnson, R.K., Hill, D.T. et al. (1986) Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J. Med. Chem., 29, 218-223.
74. Berners-Price, S.J. and Sadler, P.J. (1988) Phosphines and metal phosphine complexes: relationship of chemistry to anticancer and other biological activity. Struct. Bond., 70, 27-102.
75. Hickey, J.L., Ruhayel, R.A., Barnard, P.J. et al. (2008) Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc., 130, 12570-12571.
76. Suresh, D., Balakrishna,M.S., Rathinasamy, K. et al. (2008)Water-soluble cyclodiphosphazanes: synthesis, gold(I) metal complexes and their in vitro antitumor studies. Dalton Trans., 2812-2814.
77. Viry, E., Battaglia, E., Deborde, V. et al. (2008) A sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells. ChemMedChem, 3, 1667-1670.
78. Gabrielli,W.F.,Nogai, S.D., Nell, M. et al. (2012) Neutral mononuclear and dinuclear complexes of gold(I) featuring azole ligands: synthesis, structure and cytotoxicity. Polyhedron, 34 (1), 188-197.
79. Yan, K., Lok, C.-N., Bierla, K. and Che, C.-M. (2010) Gold(I) complex of N,N'-disubstituted cyclic thiourea with in vitro and in vivo anticancer properties-potent tight-binding inhibition of thioredoxin reductase. Chem. Commun., 46, 7691-7693.
80. Rigobello, M.P., Folda, A., Dani, B. et al. (2008) Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur. J. Pharmacol., 582, 26-34.
81. Stallings-Mann, M., Jamieson, L., Regala, R.P. et al. (2006) A novel small-molecule inhibitor of protein kinase C iota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res., 66, 1767-1774.
82. Edrogan, E., Lamark, T., Stallings-Mann, M. et al. (2006) Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Cι. J. Biol. Chem., 281, 28450-28459.
83. Tiekink, E.R.T. (2002) Gold derivatives for the treatment of cancer. Crit. Rev. Oncol. Hemat., 42, 225-248.
84. Barreiro, E., Casas, J.S., Couce, M.D. et al. (2008) Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates. J. Inorg. Biochem., 102, 184-192.
85. Casas, J.S., Castellano, E.E., Couce, M.D. et al. (2006) A gold(I) complex with a vitamin K3 derivative: characterization and antitumoral activity. J. Inorg. Biochem., 100, 1858-1860.
86. Casas, J.S., Castellano, E.E., Couce, M.D. et al. (2007) Novel gold(I) 7-azacoumarin complex: synthesis, structure, optical properties, and cytotoxic effects. Inorg. Chem., 46, 6236-6238.
87. Ott, I., Qian, X. and Xu, Y. (2009) A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J. Med. Chem., 52, 763-770.
88. Bagowski, C.P., You, Y., Scheffler, H. et al., (2009) Naphthalimide gold(I) phosphine complexes as anticancer metallodrugs. Dalton Trans., 10799-10805.
89. Mullice, L.A., Mottram, H.J., Hallett, A.J. and Pope, S.J.A. (2012) Gold(I) complexes incorporating emissive mercapto-pteridine ligands: syntheses, X-ray structure, luminescence and preliminary cytotoxic evaluation. Eur. J. Inorg. Chem., 2012, 3054-3060.
90. Vergara, E., Casini, A., Sorrentino, F. et al. (2010) Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands. ChemMedChem, 5, 96-102.
91. Vergara, E., Cerrada, E., Clavel, C. et al. (2011) Thiolato gold(I) complexes containing water-soluble phosphane ligands: a characterization of their chemical and biological properties. Dalton Trans., 40, 10927-10935.
92. Galassi, R., Burini, A., Ricci, S. et al. (2012) Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents. Dalton Trans., 41, 5307-5318.
93. Schuh, E., Valiahdi, S.M., Jakupec, M.A. et al. (2009) Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes. Dalton Trans., 10841-10845.
94. Berners-Price, S.J., Jarrett, P.S. and Sadler, P.J. (1987) 31P NMR studies of [Au2(μ-dppe)]2+ antitumor complexes. Conversion into [Au(dppe)2]+ induced by thiols and blood plasma. Inorg. Chem., 26, 3074-3077.
95. Berners-Price, S.J., Girard, G.R., Hill, D.T. et al. (1990) Cytotoxicity and antitumour activity of some tetrahedral bis(diphosphino)gold(I) chelates. J. Med. Chem., 33, 1386-1392.
96. Mirabelli, C.K., Hill, D.T., Faucette, L.F. et al., (1987) Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J. Med. Chem., 30, 2181-2190.
97. McKeage, M.J., Berners-Price, S.J., Galettis, P. et al., (2000) Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother. Pharmacol., 46, 343-350.
98. Rackham, O., Nichols, S.J., Leedman, P.J. et al. (2007) A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem. Pharmacol., 74, 992-1002.
99. Wang, Y., Liu,M., Cao, R. et al. (2013) A soluble bis-chelated gold(I) diphosphine compound with strong anticancer activity and low toxicity. J. Med. Chem., 56, 1455-1466.
100. Wetzel, C., Kunz, P.C., Kassack, M.U. et al. (2011) Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition. Dalton Trans., 40 (36), 9212-9220.
101. Healy, P.C., Loughrey, B.T., Williams, M.L. and Parsons, P.G. (2010) Synthesis, structure and cytotoxicity studies of four-coordinate bis(cis-bis(diphenylphosphino)ethene) gold(I) complexes, [Au(dppey)2]X. J. Inorg. Biochem., 104, 625-631.
102. McKeage, M.J., Maharaj, L. and Berners-Price, S.J. (2002) Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria. Coord. Chem. Rev., 232, 127-135.
103. Modica-Napolitano, J.S. and Aprille, J.R. (2001) Delocalised lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Delivery Rev., 49, 63-70.
104. Chen, L.B. (1988) Mitochondrial membrane potential in living cells. Annu. Rev. Cell Biol., 4, 155-181.
105. Rush, G.F., Alberts, D.W., Meunier, P. et al. (1987) In vivo and in vitro hepatotoxicity of a novel antineoplastic agent, SK&F 101772, in male beagle dogs. Toxicologist, 7, 59.
106. Hoke, G.D., Rush, G.F., Bossard, G.E. et al. (1988) Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines. J. Biol. Chem., 263, 11203-11210.
107. Smith, P.F., Hoke, G.D., Alberts, D.W. et al. (1989) Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes. J. Pharmacol. Exp. Ther., 249, 944-950.
108. Hoke, G.D., Macia, R.A., Meunier, P.C. et al. (1989) In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit. Toxicol. Appl. Pharmacol., 100, 293-306.
109. Liu, J.J., Galettis, P., Farr, A. et al. (2008) In vitro antitumour and hepatotoxicity profiles ofAu(I) andAg(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. J. Inorg. Biochem., 102, 303-310.
110. Humphreys, A.S., Filipovska, A., Berners-Price, S.J. et al. (2007) Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity. Dalton Trans., 4943-4950.
111. Pillarsetty, N., Katti, K.K., Hoffman, T.J. et al. (2003) In vitro and in vivo antitumor properties of Tetrakis((trishydroxymethyl)phosphine)gold(I) Chloride. J. Med. Chem., 46, 1130-1132.
112. Higginbotham, M.L., Henry, C.J., Katti, K.V. et al. (2003) Preclinical tolerance and pharmacokinetic assessment of MU-Gold, a novel chemotherapeutic agent, in laboratory dogs. Vet. Ther., 4, 76-82.
113. Santini, C., Pellei, M., Papini, G. et al. (2011) In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands. J. Inorg. Biochem., 105, 232-240.
114. Bourissou, D., Guerret, O., Gabbai, F. and Bertrand, G. (2000) Stable carbenes. Chem. Rev., 100, 39-92.
115. Herrmann, W.A. and Köcher, C. (1997) N-heterocyclic carbenes. Angew. Chem., Int. Ed. Engl., 36, 2162-2187.
116. Herrmann,W.A. (2002) N-heterocyclic carbenes: a new concept in organometallic catalysis. Angew. Chem. Int. Ed., 41, 1290-1309.
117. Nolan, S.P. (ed) (2006) N-heterocyclic Carbenes in Synthesis, Wiley-VCH Verlag GmbH, Weinheim.
118. Díez-González, S., Marion, N. and Nolan, S.P. (2009) N-heterocyclic carbenes in late transition metal catalysis. Chem. Rev., 109, 3612-3676.
119. Scholl, M., Ding, S., Lee, C.W. and Grubbs, R.H. (1999) Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. Org. Lett., 1, 953-956.
120. Hindi, K.M., Panzner, M.J., Tessier, C.A. et al. (2009) The medicinal applications of imidazolium carbene - metal complexes. Chem. Rev., 109, 3859-3884.
121. Gasser, G., Ott, I. and Metzler-Nolte, N. (2011) Organometallic anticancer compounds. J. Med. Chem., 54, 3-25.
122. Gautier, A. and Cisnetti, F. (2012) Advances in metal-carbene complexes as potent anti-cancer agents. Metallomics, 4, 23-32.
123. Oehninger, L., Rubbiani, R. and Ott, I. (2013) N-heterocyclic carbene metal complexes in medicinal chemistry. Dalton Trans., 42, 3269-3284.
124. Liu, W. and Gust, R. (2013) Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem. Soc. Rev., 42, 755-773.
125. Lin, J.C.Y., Huang, R.T.W., Lee, C.S. et al. (2009) Coinage metal - N-heterocyclic carbene complexes. Chem. Rev., 109, 3561-3598.
126. Baker, M.V., Barnard, P.J., Berners-Price, S.J. et al. (2006) Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity. Dalton Trans., 3708-3715.
127. Kunz, P.C.,Wetzel, C.,Kogel, S. et al. (2011) [(C3H4N2)2Au]Cl-a bis protic gold(I)-NHC. Dalton Trans., 40, 35-37.
128. Horvath, U.E.I., Bentivoglio, G., Hummel, M. et al., (2008) A cytotoxic bis(carbene)gold(I) complex of ferrocenyl complexes: synthesis and structural characterisation. New J. Chem., 32, 533-539.
129. Siciliano, T.J., Deblock, M.C., Hindi, K.M. et al. (2011) Synthesis and anticancer properties of gold(I) and silver(I) N-heterocyclic carbene complexes. J. Organomet. Chem., 696, 1066-1071.
130. Schuh, E., Pflüger, C., Citta, A. et al. (2012) Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. J. Med. Chem., 55, 5518-5528.
131. Liu, W., Bensdorf, K., Proetto, M. et al. (2011) NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents. J. Med. Chem., 54, 8605-8615.
132. Liu,W., Bensdorf, K., Proetto,M. et al. (2012) Synthesis, characterization, and in vitro studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes. J. Med. Chem., 55, 3713-3724.
133. Kaps, L., Biersack, B., Müller-Bunz, H. et al. (2012) Gold(I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities. J. Inorg. Biochem., 106, 52-58.
134. Urig, S., Fritz-Wolf, K., Réau, R. et al. (2006) Undressing of phospine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew. Chem. Int. Ed., 45, 1881-1886.
135. Rubbiani, R., Kitanovic, I., Alborzinia, H. et al. (2010) Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J. Med. Chem., 53, 8608-8618.
136. Rubbiani, R., Can, S., Kitanovic, I. et al. (2011) Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. J. Med. Chem., 54, 8646-8657.
137. Almássy, A., Nagy, C.E., Bényei, A.C. and Joó, F. (2010) Novel sulfonated N-heterocyclic carbene gold(I) complexes: homogeneous gold catalysis for the hydration of terminal alkynes in aqueous media. Organometallics, 29, 2484-2490.
138. Pellei, M., Gandin,V.,Marinelli, M. et al. (2012) Synthesis and biological activity of ester- and amide-functionalized imidazolium salts and related water-soluble coinage metal N-heterocyclic carbene complexes. Inorg. Chem., 51, 9873-9882.
139. Baker, M.V., Barnard, P.J., Berners-Price, S.J. et al. (2005) Synthesis and structural characterization of linear Au(I) N-heterocyclic carbene complexes: new analogues of the Au(I) phosphine drug Auranofin. J. Organomet. Chem., 690, 5625-5635.
140. Weaver, J., Gaillard, S., Toye, C. et al. (2011) Cytotoxicity of gold(I) N-heterocyclic carbene complexes assessed by using human tumor cell lines. Chem. Eur. J., 17, 6620-6624.
141. Haque, R.A., Iqbal, M.A., Ahamed, M.B.K. et al. (2012) Design, synthesis and structural studies of meta-xylyl linked bis-benzimidazolium salts: potential anticancer agents against 'human colon cancer'. Chem. Cent. J., 6, 68.
142. Barnard, P.J., Baker, M.V., Berners-Price, S.J. et al. (2004) Dinuclear gold(I) complexes of bridging bidentate carbene ligands: synthesis, structure and spectroscopic characterisation. Dalton Trans., 1038-1047.
143. Barnard, P.J., Baker, M.V., Berners-Price, S.J. and Day, D.A. (2004) Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents. J. Inorg. Biochem., 98, 1642-1647.
144. Barnard, P.J., Wedlock, L.E., Baker, M.V. et al. (2006) Luminescence studies of the intracellular distribution of a dinuclear gold(I) N-heterocyclic carbene complex. Angew. Chem. Int. Ed., 45, 5966-5970.
145. Bowmaker, G.A. (1999) Spectroscopic methods in gold chemistry, in Gold: Progress in Chemistry Biochemistry and Technology (ed H. Schmidbaur), John Wiley & Sons, Ltd, Chichester, pp. 841-881.
146. Assefa, Z., McBurnett, B.G., Staples, R.J. et al. (1995) Syntheses, structures, and spectroscopic properties of gold(I) complexes of 1,3,5-triaza-7-phosphaadamantane (TPA). Correlation of the supramolecular Au• • •Au interaction and photoluminescence for the species (TPA)AuCl and [(TPA-HCl)AuCl]. Inorg. Chem., 34, 75-83.
147. van Zyl, W.E., López-de-Luzuriaga, J.M., Mohamed, A.A. et al. (2002) Dinuclear gold(I) dithiophosphonate complexes: synthesis, luminescent properties, and X-ray crystal sructures of [AuS2PR(OR')]2 (R=Ph, R' =C5H9; R=4-C6H4OMe, R' =(1S,5R,2S)-(-)-Menthyl; R=Fc, R' =(CH2)2O(CH2)2OMe). Inorg. Chem., 41, 4579-4589.
148. Coker, N.L., Krause Bauer, J.A. and Elder, R.C. (2004) Emission energy correlates with inverse of gold-gold distance for various [Au(SCN)2]- salts. J. Am. Chem. Soc., 126, 12-13.
149. Wedlock, L.E., Aitken, J.B., Berners-Price, S.J. and Barnard, P.J. (2013) Bromide ion binding by a dinuclear gold(I) N-heterocyclic carbene complex: a spectrofluorescence and X-ray absorption spectroscopic study. Dalton Trans., 42, 1259-1266.
150. Wedlock, L.E., Barnard, P.J., Baker, M.V. et al. (2007) Probing the intracellular distribution of dinuclear luminescent Au(I) N-heterocyclic carbene complexes: potential antitumour agents that target mitochondria. J. Biol. Inorg. Chem., 12 (Suppl 1), S50.
151. Wedlock, L.E. (2011) A study into the chemistry, spectroscopic properties, and subcellular distribution of some gold(I) complexes of pharmacological interest. PhD Thesis. University of Western Australia.
152. Sadler, P.J., Nasr, M. and Narayanan, V.L. (1984) The design of metal complexes as anticancer agents, in Platinum Coordination Complexes in Cancer Chemotherapy (eds M.P. Hacker, E.B. Douple and I.H. Krakoff), Martinus Nijhoff Publishing, Boston, MA, pp. 290-304.
153. Parish, R.V., Howe, B.P.,Wright, J.P. et al. (1996) Chemical and biological studies of dichloro(2-((dimethylamino)-methyl)phenyl)gold(III). Inorg. Chem., 35, 1659-1666.
154. Buckley, R.G., Elsome, A.M., Fricker, S.P. et al. (1996) Antitumor properties of some 2-[(dimethylamino)methyl]-phenylgold(III) complexes. J. Med. Chem., 39, 5208-5214.
155. Messori, L., Marcon, G., Cinellu, M.A. et al. (2004) Solution chemistry and cytotoxic properties of novel organogold(III) compounds. Bioorg. Med. Chem., 12, 6039-6043.
156. Coronnello, M., Mino, E., Caciagli, B. et al. (2005) Mechanism of cytototoxicity of selected organogold(III) compounds. J. Med. Chem., 48, 6761-6765.
157. Fan, M., Yang, C.T., Ranford, J.D. et al. (2003) Chemical and biological studies of the dichloro(2-phenylpyridine) gold(III) complex and its derivatives. Dalton Trans., 2680-2685.
158. Fan, D.M., Yang, C.T., Ranford, J.D. et al. (2003) Synthesis, characterization, and biological activities of 2-phenylpyridine gold(III) complexes with thiolate ligands. Dalton Trans., 3376-3381.
159. n+ compounds: synthesis and cytotoxic properties. Chem. Eur. J., 12, 5253-5266.
160. Sun, R.W.-Y., Lok, C.-N., Fong, T.T.-H. et al. (2013) A dinuclear cyclometalated gold(III)-phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo. Chem. Sci., 4, 1979-1988.
161. Zhang, J.-J., Lu, W., Sun, R.W.-Y. and Che, C.-M. (2012) Organogold(III) supramolecular polymers for anticancer treatment. Angew. Chem. Int. Ed., 51, 4882-4886.
162. Yan, J.J., Chow, A.L.-F., Leung, C.-H. et al. (2010) Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. Chem. Commun., 46, 3893-3895.
163. Zou, T., Lum, C.T., Chui, S.S.-Y. and Che, C.-M. (2013) Gold(III) complexes containing N-heterocyclic carbene ligands: thiol "switch-on" fluorescent probes and anti-cancer agents. Angew. Chem. Int. Ed., 52, 2930-2933.
164. Che, C.-M., Sun, R.W.-Y., Yu,W.-Y. et al. (2003) Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem. Commun., 1718-1719.
165. Wang, Y., He, Q.-H., Sun, R.W.-Y. et al. (2005) Gold(III)porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res., 65, 11553-11564.
166. Lum, C.T., Yang, Z.F., Li, H.Y. et al. (2006) Gold(III) compound in a novel chemocytotoxic agent for hepatocellular carcinoma. Int. J. Cancer, 118, 1527-1538.
167. Wang, Y., He, Q.-Y., Che, C.-M. and Chiu, J.-F. (2006) Proteomic characterization of the cytotoxic mechanism of gold(III) porphyrin 1a, a potential anticancer drug. Proteomics, 6, 131-142.
168. Wang, Y., He, Q.-Y., Sun, R.W.-Y. et al. (2007) Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. Eur. J. Pharmacol., 554, 113-122.
169. Wang, Y., He, Q.-Y., Che, C.-M. et al. (2008) Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways. Biochem. Pharmacol., 75, 1282-1291.
170. To, Y.F., Sun, R.W.-Y., Chen, Y. et al. (2009) Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int. J. Cancer, 124, 1971-1979.
171. Li,W., Xie, Y., Sun, R.W.Y. et al. (2009) Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition. Br. J. Cancer, 101, 342-349.
172. Sun, R.W.-Y. and Che, C.-M. (2009) The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Coord.Chem. Rev., 253, 1682-1691.
173. Tu, S., Wai-Yin Sun, R., Lin, M.C.M. et al. (2009) Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer, 115, 4459-4469.
174. Lum, C.T., Huo, L., Sun, R.W.-Y. et al. (2011) Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis. Acta Oncol., 50, 719-726.
175. Lum, C.T., Wong, A.S.-T., Lin, M.C.M. et al., (2013) A gold(III) porphyrin complex as an anti-cancer candidate to inhibit growth of cancer-stem cells. Chem. Commun., 49, 4364-4366.
176. Che, C.-M. and Sun, R.W.-Y. (2011) Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment. Chem. Commun., 47, 9554-9560.
177. Lum, C.T., Liu, X., Sun, R.W.-Y. et al. (2010) Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro. Cancer Lett., 294, 159-166.
178. Messori, L., Abbate, F., Marcon, G. et al. (2000) Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. J. Med. Chem., 43, 3541-3548.
179. Marcon, G., Carotti, S., Coronnello,M. et al. (2002) Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. J. Med. Chem., 45, 1672-1677.
180. Casini, A., Cinellu,M.A., Minghetti, G. et al. (2006) Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. J. Med. Chem., 49, 5524-5531.
181. Gabbiani, C., Casini, A., Messori, L. et al. (2008) Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. Inorg. Chem., 47, 2368-2379.
182. Casini,A.,Kelter, G., Gabbiani, C. et al. (2009) Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J. Biol. Inorg. Chem., 14, 1139-1149.
183. Yang, T., Tu, C., Zhang, J. et al. (2003) Novel Au(III) complexes of aminoquinoline derivatives: crystal structure, DNA binding and cytotoxicity against melanoma and lung tumour cells. Dalton Trans., 3419-3424.
184. Shi, P., Jiang, Q., Lin, J. et al. (2006) Gold(III) compounds of 1,4,7-triazacyclononane showing high cytotoxicity against A-549 and HCT-116 tumor cell lines. J. Inorg. Biochem., 100, 939-945.
185. Shi, P., Jiang, Q., Zhao, Y. et al. (2006) DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: the impact of steric and electrostatic effects. J. Biol. Inorg. Chem., 11, 745-752.
186. Ronconi, L., Giovagnini, L., Marzano, C. et al. (2005) Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. Inorg. Chem., 44, 1867-1881.
187. Ronconi, L., Marzano, C., Zanello, P. et al. (2006) Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding and hemolytic properties. J. Med. Chem., 49, 1648-1657.
188. Milacic, V., Chen, D., Ronconi, L. et al. (2006) A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res., 66, 10478-10486.
189. Milacic, V. and Dou, Q.P. (2009) The tumor proteasome as a novel target for gold(III) complexes: Implications for breast cancer therapy. Coord. Chem. Rev., 253, 1649-1660.
190. Cattaruzza, L., Fregona, D., Mongiat, M. et al. (2011) Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int. J. Cancer, 128, 206-215.
191. Saggioro, D., Rigobello, M.P., Paloschi, L. et al. (2007) Gold(III) - dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol., 14, 1128-1139.
192. Navarro, M., Gabbiani, C., Messori, L. and Gambino, D. (2010) Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. Drug Discov. Today, 15, 1070-1078.
193. Navarro, M., Vasquez, F., Sanchez-Delgado, R.A. et al. (2004) Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes. J. Med. Chem., 47, 5204-5209.
194. Vieites, M., Smircich, P., Guggeri, L. et al. (2009) Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action. J. Inorg. Biochem., 103, 1300-1306.
195. Fricker, S.P., Mosi, R.M., Cameron, B.R. et al. (2008) Metal compounds for the treatment of parasitic diseases. J. Inorg. Biochem., 102, 1839-1845.
196. Alger, H.M. and Williams, D.L. (2002) The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol. Biochem. Parasitol., 121, 129-139.
197. Andricopulo, A.D., Akoachere, M.B., Krogh, R. et al., (2006) Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg. Med. Chem. Lett., 16, 2283-2292.
198. Rosenthal, P.J. (2004) Cysteine proteases of malaria parasites. Int. J. Parasitol., 34, 1489-1499.
199. Micale, N., Cinellu, M.A., Maiore, L. et al. (2011) Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro. J. Inorg. Biochem., 105, 1576-1579.
200. Gabbiani, C., Messori, L., Cinellu, M.A. et al. (2009) Outstanding plasmodicidal properties within a small panel of metallic compounds: hints for the development of new metal-based antimalarials. J. Inorg. Biochem., 103, 310-312.
201. Khanye, S.D., Smith, G.S., Lategan, C. et al. (2010) Synthesis and in vitro evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity. J. Inorg. Biochem., 104, 1079-1083.
202. Becker, K., Tilley, L., Vennerstrom, J.L. et al. (2004) Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int. J. Parasitol., 34, 163-189.
203. Magherini, F., Modesti, A., Bini, L. et al. (2010) Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J. Biol. Inorg. Chem., 15, 573-582.
204. Guidi, F., Landini, I., Puglia, M. et al. (2012) Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. Metallomics, 4, 307-314.
205. Gabbiani, C., Scaletti, F., Massai, L. et al. (2012) Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. Chem. Commun., 48, 11623-11625.
206. Lemke, J., Pinto, A., Niehoff, P. et al. (2009) Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates. Dalton Trans., 7063-7070.
207. Köster, S.D., Alborzinia, H., Can, S. et al. (2012) A spontaneous gold(I)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line. Chem. Sci., 3 (6), 2062-2072.
208. Kouodom, M.N., Boscutti, G., Celegato, M. et al. (2012) Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy. J. Inorg. Biochem., 117, 248-260.
209. Kouodom, M.N., Ronconi, L., Celegato, M. et al. (2012) Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics. J. Med. Chem., 55, 2212-2226.